Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

Study population

The BioFINDER study was approved by the Regional Ethics Committee in Lund, Sweden (case number 2014/223), and all participants gave their written informed consent to participate in the study. Samples for the validation cohort were collected as part of a phase 3 clinical trial conducted in accordance with the Declaration of Helsinki for experiments involving human research. All participants gave their informed consent to participate in the study.

BioFINDER cohort

Cognitively unimpaired controls (n = 65) and patients with MCI⁴³ (n = 29), AD dementia⁴⁴ (n = 43), PD⁴⁵ (n = 10), PDD⁴⁶ (n = 17), PSP⁴⁷ (n = 6), DLB⁴⁸ (n = 7), CBS⁴⁹ (n = 7) and FTD^50,51 (n = 10) were recruited from the Swedish BioFINDER study. All participants underwent a medical history, complete neurologic examination, neuropsychological testing and LP. Two LPs were…